EX-32.1 6 ctso-20241231xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. Section 1350, AS

ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of CytoSorbents Corporation (the “Company”) for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Phillip P. Chan, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief: (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Signature

    

Title

    

Date

 

 

 

 

 

/s/ Dr. Phillip P. Chan

 

Chief Executive Officer

 

March 31, 2025

Dr. Phillip P. Chan

 

(Principal Executive Officer) and Director